NO953699L - Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav - Google Patents

Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav

Info

Publication number
NO953699L
NO953699L NO953699A NO953699A NO953699L NO 953699 L NO953699 L NO 953699L NO 953699 A NO953699 A NO 953699A NO 953699 A NO953699 A NO 953699A NO 953699 L NO953699 L NO 953699L
Authority
NO
Norway
Prior art keywords
nucleic acid
molecules encoding
acid molecules
applications
tumor rejection
Prior art date
Application number
NO953699A
Other languages
English (en)
Norwegian (no)
Other versions
NO953699D0 (no
Inventor
Beatrice Gaugler
Thierry Boon-Falleur
Benoit Van Den Eynde
Pierre Van Der Bruggen
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO953699D0 publication Critical patent/NO953699D0/no
Publication of NO953699L publication Critical patent/NO953699L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Casings For Electric Apparatus (AREA)
NO953699A 1993-03-26 1995-09-20 Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav NO953699L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/037,230 US6235525B1 (en) 1991-05-23 1993-03-26 Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
PCT/US1994/002877 WO1994023031A1 (en) 1993-03-26 1994-03-17 Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof

Publications (2)

Publication Number Publication Date
NO953699D0 NO953699D0 (no) 1995-09-20
NO953699L true NO953699L (no) 1995-11-20

Family

ID=21893179

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953699A NO953699L (no) 1993-03-26 1995-09-20 Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav

Country Status (15)

Country Link
US (6) US6235525B1 (de)
EP (1) EP0690915B1 (de)
JP (1) JP3594307B2 (de)
KR (1) KR100288749B1 (de)
CN (1) CN1110556C (de)
AT (1) ATE229072T1 (de)
AU (1) AU685790B2 (de)
CA (1) CA2159098C (de)
DE (1) DE69431834T2 (de)
FI (1) FI954536A7 (de)
NO (1) NO953699L (de)
NZ (1) NZ263693A (de)
TW (1) TW432111B (de)
WO (1) WO1994023031A1 (de)
ZA (1) ZA941644B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40089E1 (en) * 1991-05-23 2008-02-19 Ludwig Institute For Cancer Research Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
WO1997013858A2 (en) * 1995-10-12 1997-04-17 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
TR200002284T2 (tr) 1998-02-05 2000-11-21 Smithkline Beecham Biologicals S.A. Mage ailesinden tümör ile ilgili tümör türevleri
US6446109B2 (en) * 1998-06-29 2002-09-03 Sun Microsystems, Inc. Application computing environment
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7314926B1 (en) 1999-04-08 2008-01-01 Antisoma Research Limited Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
IT1312568B1 (it) * 1999-05-21 2002-04-22 Genera Spa Peptidi immunogenici e loro uso.
JP2003512829A (ja) 1999-10-22 2003-04-08 アヴェンティス パストゥール リミテッド 改変型ｇｐ１００およびその使用
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
CA2408328C (en) * 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US20030104570A1 (en) * 2000-06-26 2003-06-05 Cabezon Silva Teresa Elisa Virginia Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
WO2002083945A2 (en) 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnosis and treatment of cancer: i
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
EP1864691B1 (de) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modifizierte CEA-Nukleinsäure und entsprechende Expressionsvektoren
EP1556082A1 (de) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Impfstoffe gegen krebs mit hochdosierten zytokinen als adjuvans
ATE506444T1 (de) * 2003-10-08 2011-05-15 Sanofi Pasteur Ltd Modifizierter cea/b7-vektor
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
EP2224954B1 (de) 2007-11-07 2014-01-08 Celldex Therapeutics, Inc. Menschliche dendritische und epithelzellen 205 (dec-205) bindende antikörper
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
UA103316C2 (uk) 2008-03-14 2013-10-10 Санофі Пастер Біолоджікс Ко. Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
MX339621B (es) 2010-04-13 2016-06-02 Celldex Therapeutics Inc * Anticuerpos que se unen a cd27 humano y uso de los mismos.
HRP20250981T1 (hr) 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2925348B1 (de) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualisierte impfstoffe gegen krebs
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
JP6449338B2 (ja) 2014-06-06 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
JP7044551B2 (ja) 2014-09-10 2022-03-30 ジェネンテック， インコーポレイテッド 免疫原性変異体ペプチドスクリーニングプラットフォーム
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
CN108738324B (zh) 2015-11-19 2022-06-21 百时美施贵宝公司 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
KR102414558B1 (ko) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. 인간 cd40에 결합하는 효능성 항체 및 이의 용도
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
US20210187023A1 (en) 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
JP2021515588A (ja) 2018-01-26 2021-06-24 ケンブリッジ エンタープライズ リミティッド ペプチド交換蛋白質
KR20210044220A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
US12329816B2 (en) 2018-08-24 2025-06-17 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
CA3146248A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
JP2024504912A (ja) 2020-12-30 2024-02-02 イミュノミック セラピューティックス， インコーポレイテッド 抗ｈｖｅｍ抗体
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61104788A (ja) * 1984-10-26 1986-05-23 Teijin Ltd 核酸塩基配列
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof

Also Published As

Publication number Publication date
US6565857B1 (en) 2003-05-20
US6025474A (en) 2000-02-15
DE69431834D1 (de) 2003-01-16
WO1994023031A1 (en) 1994-10-13
NZ263693A (en) 1996-07-26
CN1093751A (zh) 1994-10-19
JPH08508402A (ja) 1996-09-10
US6946289B1 (en) 2005-09-20
CA2159098C (en) 2003-04-29
US6599699B1 (en) 2003-07-29
FI954536A0 (fi) 1995-09-25
FI954536L (fi) 1995-09-25
JP3594307B2 (ja) 2004-11-24
US6552180B1 (en) 2003-04-22
EP0690915A1 (de) 1996-01-10
EP0690915A4 (de) 1997-11-12
NO953699D0 (no) 1995-09-20
ZA941644B (en) 1994-10-12
KR100288749B1 (ko) 2001-05-02
TW432111B (en) 2001-05-01
CA2159098A1 (en) 1994-10-13
DE69431834T2 (de) 2003-09-18
EP0690915B1 (de) 2002-12-04
US6235525B1 (en) 2001-05-22
FI954536A7 (fi) 1995-09-25
AU685790B2 (en) 1998-01-29
AU6447594A (en) 1994-10-24
ATE229072T1 (de) 2002-12-15
CN1110556C (zh) 2003-06-04

Similar Documents

Publication Publication Date Title
NO953699L (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
NO955063L (no) Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
BR0008635A (pt) Kit para radiomarcação de proteìnas com ìtrio-90
DE60038104D1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
AR038568A1 (es) Anticuerpos anti-a beta y su uso
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DK0710228T3 (da) Hydraziner med N3S-konfiguration som radionuclidchelatorer
BR9915940A (pt) Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
ATE242323T1 (de) Transportprotein, das den transport von kationischen xenobiotika und/oder pharmaka bewirkt, dafür kodierende dna-sequenzen und deren verwendung
DK388789A (da) Hybridderivat af humant protein d, dets fremstilling og anvendelse samt dna, som koder derfor, og genstruktur og vaertscelle indeholdende denne dna
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
DK0804467T3 (da) Isolerede, trunkerede nukleinsyremolekyler, som koder for GAGE-tumorafstødningsantigen
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
ES2150937T3 (es) Autotaxina: proteina estimulante de la motilidad util en el diagnostico y terapia del cancer.
ATE175205T1 (de) Neue urethan enthaltende aminosteroid verbindungen
NO965087L (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
DK102787D0 (da) Isohexidnucleosider og farmaceutiske praeparater indeholdende disse
FI960839A0 (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
BR9909576A (pt) Genes de receptor de transferrina de moraxella
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application